The companies that win will not simply have one strong drug
The first step was a survey that took four minutes to complete
For example, in a clinical trial for Wegovy, 4% of adults who have type 2 diabetes and a BMI over 27 (considered overweight) developed diabetic retinopathy, a potential complication of diabetes that leads to blood vessel damage in the retina
Often the first-line option for patients new to GLP-1 therapy
Any savings on health spending because of obesity drugs may take many years and may not accrue to the Medicaid program if individuals experience shifts in coverage, so states may not be factoring long-term savings into coverage decisions
Within this specific population, GLP-1 RAs exhibit major reductions in BW, BMI, WC, and SBP